乌斯特基努马布治疗性结肠炎的有效性和持续性:城追溯队列研究
Katsuyoshi Ando1, Mikihiro Fujiya1, Nobuhiro Ueno2
1Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University Asahikawa, Japan.
Crohn's & colitis 360
|May 7, 2024
概括
乌斯特基努马布 (UST) 对性结肠炎 (UC) 有效,表现出高响应和缓解率,特别是在以前没有使用过生物药物的患者中. 早期反应预测了长期的持久性,并具有有利的安全性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于性结肠炎 (UC) 中的乌斯特基努马布 (UST) 有有限的现实世界数据,特别是对于以前没有使用过生物药物的患者.
- 这项研究解决了对UC患者UST有效性和安全性的实际证据的需求.
研究的目的:
- 评估乌斯特基努马布 (UST) 对治疗性结肠炎 (UC) 的实际有效性和安全性.
- 确定治疗反应和UC患者UST长期持久性的预测因素.
主要方法:
- 从2020年3月到2023年1月,在7家医院接受UST治疗的150名UC患者的回顾性分析.
- 从第8周到第56周对临床疗效和持续性的评估,包括对预测因素的单变量和多变量分析.
主要成果:
- UST表现出高响应率 (72.8%在第8周,73.2%在第56周) 和缓解率 (56.0%在第8周,63.4%在第56周).
- 与之前生物暴露的患者相比,生物素素的患者在第8周表现出更高的反应和缓解率.
- 之前暴露于抗TNF和维多利祖马布 (VDZ) 与较低的反应和缓解率有关;第8周的临床反应预测持续1年. 副作用的发生率很低 (6.4%).
结论:
- 乌斯特基努马布 (UST) 是治疗性结肠炎 (UC) 的安全有效的诱导和维持疗法.
- 慢性持续性疾病类型和先前的抗TNF/VDZ暴露对短期有效性产生了负面影响,而早期反应预测了长期的持续性.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
01:21Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
166
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
166
01:29Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126